Shandong Xinhua Pharmaceutical Company Limited Stock Shenzhen S.E.

Equities

000756

CNE000000BG1

Pharmaceuticals

End-of-day quote Shenzhen S.E. 06:00:00 2024-07-14 pm EDT 5-day change 1st Jan Change
14.41 CNY -1.97% Intraday chart for Shandong Xinhua Pharmaceutical Company Limited +1.77% -29.29%
Sales 2022 7.5B 1.03B Sales 2023 8.1B 1.12B Capitalization 10.81B 1.49B
Net income 2022 411M 56.58M Net income 2023 497M 68.41M EV / Sales 2022 2.12 x
Net Debt 2022 225M 30.99M Net Debt 2023 440M 60.62M EV / Sales 2023 1.39 x
P/E ratio 2022
11.8 x
P/E ratio 2023
7.3 x
Employees 7,104
Yield 2022
2.78%
Yield 2023
4.76%
Free-Float 60.55%
More Fundamentals * Assessed data
Dynamic Chart
Shandong Xinhua Pharmaceutical Company Limited Approves Final Cash Dividend for the Year Ended 31 December 2023, Payable on 30 July 2024 CI
Xinhua Pharmaceutical Gets Nod to Register Pregabalin Capsules MT
Shandong Xinhua Pharmaceutical Company Limited Obtains Drug Registration Certificate on Pregabalin Capsules CI
Shandong Xinhua Pharmaceutical's Two Drugs Pass Chinese Drug Regulator's Consistency Evaluation MT
Shandong Xinhua Pharmaceutical Company Limited Receives the Notice of Approval of Supplementary Drug Application from the National Medical Products Administration CI
Shandong Xinhua Pharmaceutical Company Limited Receives the Notice of Approval of Supplementary Drug Application from the National Medical Products Administration CI
Xinhua Pharmaceutical’s Sodium Bicarbonate Injection Passes Generic Drug Evaluation in China MT
Shandong Xinhua Pharmaceutical Company Limited Receives Notice of Approval of Supplementary Drug Application from the National Medical Products Administration CI
Xinhua Pharmaceutical's Depression Drug Gets Registration Approval in China MT
Shandong Xinhua Pharmaceutical Company Limited Receives Drug Registration Certificate of Escitalopram Oxalate Tablets CI
Shandong Xinhua Pharmaceutical Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Xinhua Pharma Unit's Cefaclor Capsules Passes Regulatory Evaluation MT
Shandong Xinhua Pharmaceutical Company Limited Receives Notification of Approval of Supplementary Drug Application CI
Shandong Xinhua Pharmaceutical Posts Higher 2023 Profit MT
Shandong Xinhua Pharmaceutical Proposes New Auditor MT
More news
1 day-1.97%
1 week+1.77%
Current month-0.48%
1 month-6.43%
3 months-7.57%
6 months-28.56%
Current year-29.29%
More quotes
1 week
14.01
Extreme 14.01
14.75
1 month
13.68
Extreme 13.68
15.59
Current year
13.45
Extreme 13.45
20.88
1 year
13.45
Extreme 13.45
24.72
3 years
7.32
Extreme 7.32
48.85
5 years
6.22
Extreme 6.22
48.85
10 years
4.47
Extreme 4.4692
48.85
More quotes
Date Price Change Volume
24-07-15 14.41 -1.97% 3,526,900
24-07-12 14.7 +1.10% 5,101,500
24-07-11 14.54 +2.39% 4,953,900
24-07-10 14.2 -0.07% 4,208,330
24-07-09 14.21 +0.35% 7,698,080

End-of-day quote Shenzhen S.E., July 14, 2024

More quotes
SHANDONG XINHUA PHARMACEUTICAL COMPANY LIMITED is a China-based company principally engaged in the development, production and distribution of chemical bulk drugs, preparations and medical intermediates. The Company’s main products include metamizole sodium, caffeine, aminopyrine, aspirin, hydrocortisone, pipemidic acid, ibuprofen, L-dopa, pipemidic acid tablets, compound liquorice tablets and nimodipine tablets. The Company distributes its products in domestic market and to overseas markets, including the Americas, Europe and others.
Calendar
More about the company